ReviewBiomedicines2022
Re-Definition of the Epidemiology of Cardiac Amyloidosis.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Prognostic value of left atrial function in cardiac amyloidosis: a systematic review and meta‑analysis.The international journal of cardiovascular imaging · 2026Pooled it
- Ventilatory efficiency in cardiac amyloidosis-A systematic review and meta-analysis.Physiological reports · 2025Pooled it
- Automated identification of cardiac amyloidosis using cross-modal neural networks on [Formula: see text]-Pyrophosphate SPECT imaging and clinical data.The international journal of cardiovascular imaging · 2026Article
- A Potential Approach to Bridge the Diagnostic Gap and Propose a Referral Pathway for Suspected ATTR-CA Based on Incidental Cardiac Uptake inDiagnostics (Basel, Switzerland) · 2026Article
- Physiologically relevant forms of Tc- and Re-pyrophosphate radioactive tracers and the basis of their transthyretin amyloid sensitivity.Scientific reports · 2026Article
- Myocardial radiomics of non-ischemic cardiomyopathy using cardiovascular magnetic resonance: current perspectives and future directions.Frontiers in cardiovascular medicine · 2026Review
- Identifying implementation strategies to increase the early detection of cardiac amyloidosis: a pre-implementation study.Frontiers in cardiovascular medicine · 2026Article
- Insights into Missense SNPs on Amyloidogenic Proteins.Proteomes · 2025Article
- Prevalence of amyloid deposition in distal biceps tendon ruptures: a retrospective review of intraoperative biopsy.JSES reviews, reports, and techniques · 2025Article
- A simplified cardiac amyloidosis score predicts all-cause and cardiovascular disease mortality and morbidity in the general population: the Ikaria Study.Archives of medical science : AMS · 2025Article
- First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia.ESC heart failure · 2024Article
- A Snapshot of the Most Recent Transthyretin Stabilizers.International journal of molecular sciences · 2024Review
- Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.Cardiology research · 2024Review
- Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis.World journal of cardiology · 2024Article
- Arrhythmic Risk Stratification in Cardiac Amyloidosis: A Review of the Current Literature.Journal of cardiovascular development and disease · 2024Review
- Histological assessment of cardiac amyloidosis in patients undergoing transcatheter aortic valve replacement.ESC heart failure · 2024Article
- Lights and Shadows of Clinical Applications of Cardiac Scintigraphy with Bone Tracers in Suspected Amyloidosis.Journal of clinical medicine · 2023Review
- Prevalence of Incidental Findings Suspicious for Transthyretin Cardiac Amyloidosis among Patients Undergoing Bone Scintigraphy: A Systematic Review and a Meta-Analysis.Journal of clinical medicine · 2023Review
- Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy.Pharmaceutics · 2023Review
- Machine Learning Approaches in Diagnosis, Prognosis and Treatment Selection of Cardiac Amyloidosis.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology of cardiac amyloidosis (CA), traditionally considered a rare and incurable disease, has changed drastically over the last ten years, particularly due to the advances in diagnostic methods and therapeutic options in the field of transthyretin CA (ATTR-CA). On the one hand, the possibility of employing cardiac scintigraphy with bone tracers to diagnose ATTR-CA without a biopsy has unveiled the real prevalence of the disease; on the other, the emergence of effective treatments, such as tafamidis, has rendered an early and accurate diagnosis critical. Interestingly, the following subgroups of patients have been found to have a higher prevalence of CA: elderly subjects > 75 years, patients with cardiac hypertrophy hospitalized for heart failure with preserved ejection fraction, subjects operated on for bilateral carpal tunnel syndrome, patients with cardiac hypertrophy not explained by concomitant factors and individuals with aortic valve stenosis. Many studies investigating the prevalence of CA in these particular populations have contributed to rewriting the epidemiology of the disease, increasing the awareness of the medical community for a previously underappreciated condition. In this review, we summarized the latest evidence on the epidemiology of CA according to the different clinical settings typically associated with the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.